Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $338000.0.

  • Xeris Biopharma Holdings' Depreciation & Amortization (CF) rose 1009.77% to $338000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 141.4%. This contributed to the annual value of $1.2 million for FY2024, which is 1820.0% down from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Depreciation & Amortization (CF) of $338000.0 as of Q3 2025, which was up 1009.77% from $325000.0 recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Depreciation & Amortization (CF) high stood at $391000.0 for Q3 2023, and its period low was $281000.0 during Q2 2024.
  • Its 5-year average for Depreciation & Amortization (CF) is $338631.6, with a median of $337000.0 in 2021.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Depreciation & Amortization (CF) tumbled by 2720.21% in 2024, and later soared by 1565.84% in 2025.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Depreciation & Amortization (CF) stood at $349000.0 in 2021, then increased by 5.16% to $367000.0 in 2022, then dropped by 2.18% to $359000.0 in 2023, then decreased by 12.81% to $313000.0 in 2024, then rose by 7.99% to $338000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $338000.0 for Q3 2025, versus $325000.0 for Q2 2025 and $315000.0 for Q1 2025.